Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Protein Implicated in Aberrant B-cell Survival in Transplant Disease

By BiotechDaily International staff writers
Posted on 27 Aug 2012
Ex vivo study finds that B-cells from patients with chronic graft vs. host disease (cGVHD) are in a heightened metabolic state and are resistant to apoptosis compared to patients without cGVHD, and leads to identification of a key candidate target for development of more effective drug therapies.

The research team, primarily from University of North Carolina’s Lineberger Comprehensive Cancer Center (UNC Lineberger; Chapel Hill, NC, USA), performed ex vivo analyses of peripheral B cells from 51 patients who either had or did not have active cGVHD and were greater than one year from the time of allogeneic hematopoietic stem cell (HSCT) transplantation. In addition to the finding of the aberrantly sustained activation of the B-cells from patients with cGVHD, an investigation into the mechanisms involved in this process led to the implication of a mechanistic link between this abnormal B-cell survival and the TNF family member signaling protein called BAFF, thus identifying BAFF as having an important role in the pathogenesis of cGVHD.

For patients who received bone marrow or stem cells, it is estimated that 40%-70% may experience chronic GVHD.

“Steroids are currently our only standard treatment for chronic GVHD and they are often not effective,” noted senior author Stefanie Sarantopoulos, MD, PhD, assistant professor in the division of hematology/oncology and the departments of microbiology and immunology at the UNC School of Medicine. This study offers BAFF and the BAFF-mediated signaling pathways that contribute to this “revved up” B-cell activity as potentially suitable sources of novel therapeutic targets for chronic GVHD patients.

The study was published August 15, 2012, in the journal Blood.

Related Links:

University of North Carolina’s Lineberger Comprehensive Cancer Center




comments powered by Disqus

Channels

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.